Rankings
▼
Calendar
UTHR
United Therapeutics Corporation
$24B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$799M
+11.7% YoY
Gross Profit
$711M
89.0% margin
Operating Income
$365M
45.6% margin
Net Income
$310M
38.8% margin
EPS (Diluted)
$6.41
QoQ Revenue Growth
+0.5%
Cash Flow
Operating Cash Flow
$192M
Free Cash Flow
$130M
Stock-Based Comp.
$38M
Balance Sheet
Total Assets
$7.9B
Total Liabilities
$734M
Stockholders' Equity
$7.2B
Cash & Equivalents
$1.6B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$799M
$715M
+11.7%
Gross Profit
$711M
$637M
+11.6%
Operating Income
$365M
$320M
+13.9%
Net Income
$310M
$278M
+11.3%
Revenue Segments
Tyvaso
$470M
59%
Remodulin
$135M
17%
Orenitram
$124M
16%
Unituxin
$58M
7%
Adcirca
$7M
1%
Product and Service, Other
$6M
1%
Geographic Segments
UNITED STATES
$760M
95%
Non-US
$39M
5%
← FY 2025
All Quarters
Q3 2025 →
UTHR Q2 2025 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena